NSI-566

N/A

Report date: 2024/06/26 20:00:35

Base Information

Drug NameNSI-566
Drug Alias NameNeural Stem Cells - NeuralstemHuCNS-SC - NeuralstemhCNS-SC - NeuralstemNSI-566RSCNSI-566
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Neural stem cell therapyCell and gene therapy > Cell therapy > Source of cells > Spinal Cord-derived
Mechanisms of ActionNeurons stimulantsCell replacementsNeurogenesis stimulants
TargetsEstrogen receptors
Therapy Area/IndicationsIschemic StrokeSpinal Cord InjuriesAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesHK inno.N CorporationNeuralstem Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSuzhou Neuralstem BiopharmaceuticalsNeuralstem Inc
Active IndicationsN/A
Inactive IndicationsIschemic StrokeSpinal Cord InjuriesAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A